<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03329443</url>
  </required_header>
  <id_info>
    <org_study_id>CT00964</org_study_id>
    <nct_id>NCT03329443</nct_id>
  </id_info>
  <brief_title>The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary Angiography</brief_title>
  <official_title>The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary Angiography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alhasan Mujtaba Abdul-Wahid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health-Basra Health Directorate-Al-Sader Teaching Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Baghdad</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      an interventional study to measure the possible effects of spironolactone ( an aldosterone
      antagonist) on the incidence of acute kidney injury after coronary angiography
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">November 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute kidney injury by K-DIGO guidelines</measure>
    <time_frame>48-72 hrs</time_frame>
    <description>an absolute elevation of serum creatinine of 0.5mg/dl or 25% above baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>acute kidney injury by NGAL</measure>
    <time_frame>6 hours</time_frame>
    <description>assessment of serum NGAL at admission and after 6 hrs to detect possible AKI in selected patients</description>
  </secondary_outcome>
  <other_outcome>
    <measure>safety outcome: serum potassium</measure>
    <time_frame>6 hrs</time_frame>
    <description>serum potassium after 6 hrs of angio</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>IHD</condition>
  <condition>Contrast-induced Nephropathy</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Spironolactone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>each patient will receive 200 mg of spironolactone as per his/her angiography premedications</description>
    <arm_group_label>Spironolactone</arm_group_label>
    <other_name>Active group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Each patient will receive a placebo tablet as per his/her angiography premedications</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Control group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients admitted to angiography unit

          -  over 18

          -  informed consent

        Exclusion Criteria:

          -  acute renal failure before 7 days

          -  spironolactone contraindications

          -  hyperkalemia (S.K. &gt;5.5 mEq/L)

          -  documented tumor

          -  actively taking NSAIDs, Ciclosporin, Cisplatin,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alhasan Mujtaba, BCPS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baghdad University/College of Pharmacy/Department of Clinical Pharmacy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammed A Taher, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Baghdad University/College of Pharmacy/Department of Biochemistry</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mazin A Hazzaa', Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Al-Sader teaching Hospital/Basra Cardiac Center/M.D. Cardiologist</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hassan M Al Rubaye, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Al-Sader teaching Hospital/Basra Cardiac Center/M.D. Cardiologist</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Assad H Kata, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Al-Sader teaching Hospital/Basra Cardiac Center/M.D. Cardiologist</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hayder K Abdullkreem, M.Sc</last_name>
    <role>Study Director</role>
    <affiliation>Head of the clinical laboratory department/ Al-Sader teaching hopital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hamid A Abdulsada, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Al-Sader teaching Hospital/Basra Cardiac Center/M.D. Cardiologist</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdul Ameer A Abdul Hameed, PH.D</last_name>
    <role>Study Director</role>
    <affiliation>Al-Sader teaching Hospital/Basra Cardiac Center/M.D. Cardiologist</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alhasan Mujtaba, BCPS</last_name>
    <phone>009647801601693</phone>
    <email>user11126@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohammed A Taher, Ph.D.</last_name>
    <phone>009647740487836</phone>
    <email>sad5554@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Al-Sader Teaching Hospital</name>
      <address>
        <city>Basrah</city>
        <zip>00964</zip>
        <country>Iraq</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mazin A Hazzaa, Ph.D</last_name>
      <phone>009647823329999</phone>
    </contact>
    <contact_backup>
      <last_name>Hassan M Al Rubaye, Ph.D.</last_name>
      <phone>009647801074362</phone>
      <email>hm200467@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Iraq</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>October 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Baghdad</investigator_affiliation>
    <investigator_full_name>Alhasan Mujtaba Abdul-Wahid</investigator_full_name>
    <investigator_title>Clinical pharmacy specialist</investigator_title>
  </responsible_party>
  <keyword>spironolactone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

